NIK-626; a dual inhibitor of thromboxane synthase and 5-lipoxygenase, potential candidate as a novel anti-asthma compound Source: Eur Respir J 2001; 18: Suppl. 33, 264s Year: 2001
Pharmacological properties of novel LTC4 synthase inhibitor Source: International Congress 2017 – Novel mechanisms and treatments for asthma Year: 2017
Direct relationship between inhibition of leukotriene release in lung and free plasma concentration of a LTC4 synthase inhibitor in a rat model Source: International Congress 2015 – New models for treating airway diseases Year: 2015
Effects of selective and non-selective cyclooxygenase inhibition on exhaled eicosanoids in COPD Source: Eur Respir J 2004; 24: Suppl. 48, 578s Year: 2004
No direct inhibition of NO synthases by montelukast Source: Eur Respir J 2004; 24: Suppl. 48, 578s Year: 2004
COX-1 driven biosynthesis of PGD2 during activation of human mast cells prevents formation of other prostanoids Source: Virtual Congress 2020 – Novel molecular markers and targets for asthma phenotypes Year: 2020
Quantitative assessment of cysteinyl leukotrienes in human sputum during the allergen-induced asthmatic response and the effect of GSK2190915, a 5-lipoxygenase activating protein (FLAP) inhibitor Source: Annual Congress 2011 - Diagnosis and treatment of inflammatory respiratory diseases Year: 2011
Effect of thromboxane A2 (TXA2 ) synthase inhibitor and TXA2 receptor antagonist alone and in combination on antigen-induced bronchoconstriction in guinea pigs Source: Eur Respir J 2001; 18: Suppl. 33, 264s Year: 2001
Assessment of in vivo 5-lipoxygenase (5-LO) activity in nonatopic and atopic subjects with or without asthma: effects of treatment with the 5-LO inhibitor zileuton Source: Eur Respir J 2003; 22: Suppl. 45, 101s Year: 2003
Inhibition of eosinophil migration by montelukast, a cysteinyl leukotriene receptor antagonist, through down regulation of plasmin activity Source: Eur Respir J 2004; 24: Suppl. 48, 36s Year: 2004
Effects of inducible nitric oxide synthase and xanthine oxidase inhibitors on SEB-induced interstitial pneumonia in mice Source: Eur Respir J 2002; 19: 447-457 Year: 2002
Differential actions of phosphatidyinositol 3-kinase inhibitors on respiratory burst and leukotriene C4 generation in PAF-stimulated human eosinophils Source: Eur Respir J 2003; 22: Suppl. 45, 547s Year: 2003
The novel phosphodiesterase 4 inhibitor CI-1044 inhibits in vitro LPS-induced TNFα production in whole blood of COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 34s Year: 2001
Effects of selective and unselective endothelin-receptor antagonists on prostacyclin synthase gene expression in pulmonary hypertension Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension Year: 2007
Oral administration of a new prostacyclin agonist with thromboxane synthase inhibitory activity improves bleomycin-induced lung fibrosis Source: Annual Congress 2010 - New insights in the treatment of idiopathic pulmonary fibrosis Year: 2010
15-LOXb is the enzymatic source of aspirin induced 15-HETE generation in aspirin-sensitive patients Source: Eur Respir J 2005; 26: Suppl. 49, 342s Year: 2005
5-lipoxygenase inhibitor therapy in IPF Source: Annual Congress 2008 - New therapeutic strategies in idiopathic pulmonary fibrosis Year: 2008
Effects of endothelial nitric oxide synthase enzyme, angiotensin converting enzyme and serotonin transporter genotypes on pulmonary hypertension in COPD Source: Annual Congress 2010 - Pulmonary circulation I Year: 2010
Oral N-acetylcysteine attenuates the rat pulmonary inflammatory response to antigen Source: Eur Respir J 2003; 21: 394-400 Year: 2003
Lactose-β-sitosterol inhibits ovalbumin-induced asthmatic inflammation with no influence on nitric oxide pathway Source: Annual Congress 2010 - Animal models of asthma and lung inflammation Year: 2010